Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181)
Revision as of 19:31, 24 June 2020 by Admin (talk | contribs) (Created claim: Property:P146: Item:Q11178, #quickstatements; #temporary_batch_1593027050476)
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653)
|
Publication: "COVID-19 and emerging viral infections: The case for interferon lambda"published as J. Exp. Med.; 2020 05 04 ; 217 (5); DOI: 10.1084/jem.20200653
|
